Verona Pharma Announces March 2025 Investor Conference Participation

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) has announced its participation in two major healthcare investor conferences in March 2025. The company will present corporate overviews at the TD Cowen 45th Annual Health Care Conference in Boston on March 3 at 11:10 a.m. ET, and at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10 at 8:40 a.m. ET.

The company specializes in developing treatments for chronic respiratory diseases, with their flagship product Ohtuvayre™ (ensifentrine), the first inhaled COPD maintenance therapy combining bronchodilator and anti-inflammatory properties. Webcasts of both presentations will be available on the company's website.

News Market Reaction – VRNA

+0.06%

1 alert

+0.06% News Effect

On the day this news was published, VRNA gained 0.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025:

TD Cowen 45^th Annual Health Care Conference
Date: Monday, March 3, 2025
Time: 11:10 a.m. ET / 4:10 p.m. GMT
Location: Boston, MA

Leerink Partners 2025 Global Healthcare Conference
Date: Monday, March 10, 2025
Time: 8:40 a.m. ET / 1:40 p.m. GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com
Wendy Ryan

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

When and where will Verona Pharma (VRNA) present at the TD Cowen Healthcare Conference in 2025?

Verona Pharma will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 11:10 a.m. ET.

When is Verona Pharma's (VRNA) presentation at the Leerink Partners Conference in 2025?

Verona Pharma will present at the Leerink Partners 2025 Global Healthcare Conference in Miami on March 10, 2025, at 8:40 a.m. ET.

What is Verona Pharma's (VRNA) main product Ohtuvayre used for?

Ohtuvayre (ensifentrine) is an inhaled maintenance therapy for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule.

How can investors access Verona Pharma's (VRNA) March 2025 conference presentations?

Investors can access webcasts of both conference presentations through the Events and Presentations link on the Investors page of Verona Pharma's website (www.veronapharma.com).